Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06336213
Other study ID # 20240306
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 19, 2024
Est. completion date December 15, 2024

Study information

Verified date March 2024
Source Petrovsky National Research Centre of Surgery
Contact Artem Gubko, Ph.D.
Phone +79684241490
Email gubko@artvig.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.


Description:

Various biomarkers are being used to improve the quality of prediction models aiming to improve clinical outcomes and reduce mortality in the cardiac surgery patient population. In particular, presepsin and procalcitonin have comparable prognostic value for adverse renal, cardiovascular and respiratory outcomes in cardiac surgery patients. In addition, presepsin has in-hospital, 30-day, and 6-month prognostic mortality rate value and is also highly effective for the early diagnosis of sepsis in patients in the intensive care unit. In the previous study the absence of an increase in the level of presepsin in the first 6 hours after surgery was associated with an increased risk of developing a complicated course of the postoperative period (OR 4.15, 95% CI: 1.83-9.41). The combination of two risk factors - a presepsin level at the end of surgery >519.5 pg/ml and the absence of an increase in the presepsin level in the first 6 hours after surgery was associated with an increased risk of developing a complicated course of the postoperative period (OR 5.80, 95% CI: 2. 19-15.35). The hypothesis of this study suggests that in case of insufficient prevention of infectious complications, based on the dynamics of presepsin, it is permissible to administer the broad-spectrum drug ampicillin/sulbactam 3 g. every 6 hours for at least 72 hours from the date of surgery. It is expected that changes in the tactics of antibacterial therapy will reduce the number of inflammatory complications in patients undergoing surgery on thoracic aorta.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 15, 2024
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Thoracic aorta aneurysm/dissection Exclusion Criteria: Blood sample hemolysis

Study Design


Intervention

Drug:
Ampicillin-sulbactam
If a patient meets dual criteria (presepsin > 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.

Locations

Country Name City State
Russian Federation Petrovsky Research National Centre of Surgery (Petrovsky NRCS) Moscow

Sponsors (1)

Lead Sponsor Collaborator
Petrovsky National Research Centre of Surgery

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Infectious complications rate Postoperative pneumonia, sepsis, wound infection, mediastinitis up to 10 days
Secondary Total amount of complicated patients Patients that suffer at least 1 complication in postoperative period up to 10 days
Secondary Mortality In-hospital mortality rate up to 10 days
Secondary Length of hospital stay Days spent in hospital since admission up to 10 days
Secondary Length of ICU stay Hours in ICU after the surgery up to 10 days
Secondary Multiorgan failure 2 or more organ dysfunction in postoperative period up to 10 days
See also
  Status Clinical Trial Phase
Recruiting NCT01390181 - The Effect of Losartan in Bicuspid Aortic Valve Patients N/A
Recruiting NCT00339053 - Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair Phase 4
Not yet recruiting NCT05395598 - Incidence of Major Complication in Case of Thoracic Aortic Aneurysm
Recruiting NCT00549315 - Clinical Study of Thoracic Aortic Aneurysm Exclusion N/A
Recruiting NCT05777460 - Mid- and Long-term Outcomes of Custom-made Aortic Devices
Active, not recruiting NCT05146375 - Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)
Completed NCT01082172 - South American Thoracic Stent-Graft Study N/A
Recruiting NCT03824626 - Biomechanical Reappraisal of Planning for Thoracic Endovascular Aortic Repair
Completed NCT04663074 - Intravascular Ultrasound (IVUS) in Complex Aortic Endovascular Interventions
Recruiting NCT04747626 - B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair N/A
Active, not recruiting NCT05143138 - Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries
Completed NCT00111176 - STARZ-TX2 Clinical Study: Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft N/A
Recruiting NCT05639400 - Thoraflex Hybrid and Relay Extension Post-Approval Study
Terminated NCT02735720 - The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study
Completed NCT02256163 - Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm N/A
Recruiting NCT06377033 - Using the EHR to Advance Genomic Medicine Across a Diverse Health System N/A
Recruiting NCT06094127 - Zenith Thoracic Alpha (ZTA) Post-Market Data Collection
Recruiting NCT03998631 - Comparison of Carbon Dioxide and Saline Flush to Saline Flush in TEVAR and TAVI Procedures to Reduce Cerebral Ischemia Phase 1
Completed NCT05414318 - CTAG Dissection/Trauma Post Marketing Surveillance Japan
Completed NCT04756778 - Indexed Aortic Area in Bicuspid Aortic Valve Aortopathy